Abstract
Aim To assess serum HGF concentration in individuals with schizophrenia and investigate the efficacy of zinc and B-6 therapy on these levels. Subjects and methods Serum from 18 individuals diagnosed with schizophrenia and 19 age and gender similar controls ( P = 0.18) were tested for HGF concentration using ELISAs, and tested for copper and zinc plasma levels using inductively-coupled plasma-mass spectrometry. Results HGF serum levels of individuals with schizophrenia, before zinc and B-6 therapy, were significantly lower than age and gender similar controls ( P = 0.016), and significantly lower in schizophrenia patients pre-therapy compared to post therapy ( P = 0.028). HGF levels normalized (reached levels similar to controls) post-therapy. Zinc levels in these same individuals also normalized, and perceived symptoms, particularly anxiety ( P = 0.03), improved significantly after therapy. Discussion These results suggest an association between low HGF levels and schizophrenia and demonstrate that zinc and B-6 therapy may be associated with the normalization of HGF levels and perceived improvement in symptoms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
